Scientific intelligence record

Experience 2.0

Growth-hormone fragment analog

AOD-9604

Also known as: AOD9604, Anti-Obesity Drug 9604, hGH fragment 177-191 analog

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.

Record status

Traceability partial

Last meaningful update: 9/8/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/8/2026
Last human review:: 9/8/2026

Governed reviewed evidence

Governed records, not an efficacy score or total literature count.

Evidence boundary

0 / 25

Claim-linked support versus recorded evidence.

Research gaps

Unresolved questions remain visible.

Human experience

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Governed reviewed evidence

Reviewed database records promoted through the governed publication workflow.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

No public institutional claim is represented yet

This does not mean the scientific literature contains no findings. It means no reviewed institutional claim has been represented here.

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

Amino acid sequence: YLRIVQCRSVEGSCGF

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2000 · study · Temporal status not established
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
peer_reviewed_research
2001 · study · Temporal status not established
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
peer_reviewed_research
2001 · study · Temporal status not established
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
peer_reviewed_research
2003 · study · Temporal status not established
Gateways to clinical trials.
peer_reviewed_research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

peer_reviewed_research

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Claim → Evidence

Incomplete

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Incomplete links: claim-to-evidence

Inspect 25 source paths ↓

Gateways to clinical trials.

Claim: Not linked · Evidence: 3872fce72ac584ef6624297b7fed6a97

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Reviewed jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union (EMA)

Regulator: EMA

not_approved

As of: 9/8/2026 · Temporal status not established

European Medicines Agency medicines database

United States (FDA)

Regulator: FDA

not_approved

As of: 9/8/2026 · Temporal status not established

Drugs@FDA: FDA-Approved Drugs

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.

Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.

Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.

Contradictory and qualifying evidence must remain visible rather than being silently discarded.

Absence of represented evidence is not evidence that research does not exist.

Research gaps identify unresolved questions; they are not negative conclusions.

Regulatory status is distinct from scientific evidence quality.

Media relationships provide context and explanation; they do not increase the strength of scientific evidence.

A section with no represented records is an incomplete project record, not a scientific conclusion.

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula: C78H123N23O23S2
Molecular weight: 1815.1 g/mol
Exact identity / sequence notation: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH; Cys7–Cys14 disulfide
Identity-defining modifications: 16 residues: Tyr plus human growth-hormone residues 177–191
Cys7–Cys14 disulfide
Free C-terminal carboxyl
PubChem CID: 71300630
InChIKey: Not applicable / not verified

Cyclic/disulfide identity is explicit; the schematic is not a determined fold.

Sources: NIH PubChem — AOD-9604 · reviewed 2026-09-17

Representative sequence-derived model

AOD-9604

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

No public institutional claim is represented yet

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

Gateways to clinical trials.

Follow the scientific relationships

peer_reviewed_research

Follow the record back to its source

What contributors reported

Reviewed jurisdictional records

not_approved

not_approved

Media connected to this scientific record

Read the scientific record with its boundaries intact

Practice-defining evidence

Strong supporting evidence

Contextual evidence

Signal-generating evidence

Tier and confidence answer different questions

Structural visualization and provenance

Evidence Passport

Evidence integrity map

Gateways to clinical trials.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

AOD-9604 Metabolic.

Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.

Gateways to clinical trials.

Gateways to clinical trials.

Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].

Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.

AOD-9604 does not influence the WADA hGH isoform immunoassay.

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

Current updates in the medical management of obesity.

Detection and in vitro metabolism of AOD9604.

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Obesity drugs in clinical development.

The World Anti-Doping Code International Standard: Prohibited List

Drugs@FDA: FDA-Approved Drugs database

Gateways to clinical trials.

AOD-9604 Metabolic.

Gateways to clinical trials.

Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.

Obesity drugs in clinical development.

[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].

Current updates in the medical management of obesity.

AOD-9604 does not influence the WADA hGH isoform immunoassay.

Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.

Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.

Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.

Detection and in vitro metabolism of AOD9604.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

The World Anti-Doping Code International Standard: Prohibited List

Drugs@FDA: FDA-Approved Drugs database

Regulatory review: not_approved

Regulatory review: not_approved